drug
binimetinib
Marketedupdated 3mo agoby Array BioPharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying binimetinib
- phase2Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
- phase1PF-07284892 in Participants With Advanced Solid Tumors
- phase1A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- phase4Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
- phase2Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- —UK ENcorafenib and BInimetinib Real-world Study in Melanoma
- phase1Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
- phase4The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 11, 2026
54 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Oct 18, 2033compositionUS 9562016
- Oct 18, 2033method-of-use (U-2330)US 9598376
- Oct 18, 2033method-of-use (U-2334)US 9980944
- Jul 4, 2031method-of-use (U-3737)US 93144644.9y
- Aug 27, 2030method-of-use (U-3737)US 100057614.0y
- Aug 27, 2030method-of-use (U-2333)US 98502294.0y
- Mar 13, 2027compositionUS 7777050207d
FDA exclusivities (1)
- Oct 11, 2026I-928Indication (3y)54d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that